Please login (Members) to view content or
(Nonmembers) this article.
0
No votes yet
ONS Guidelines Article
Online Exclusive Article

Management of Opioid-Induced and Non–Opioid-Related Constipation in Patients With Cancer: Systematic Review and Meta-Analysis

Pamela K. Ginex
Brian J. Hanson
Kristine B. LeFebvre
Yufen Lin
Kerri A. Moriarty
Christine Maloney
Mark Vrabel
Rebecca L. Morgan
ONF 2020, 47(6), E211-E224 DOI: 10.1188/20.ONF.E211-E224

Problem Identification: A systematic review and meta-analysis was conducted to inform the development of national clinical practice guidelines on the management of cancer constipation.

Literature Search: PubMed®, Wiley Cochrane Library, and CINAHL® were searched for studies published from May 2009 to May 2019.

Data Evaluation: Two investigators independently reviewed and extracted data from eligible studies. The Cochrane Collaboration risk-of-bias tool was used, and the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach was used to assess the certainty of the evidence.

Synthesis: For patients with cancer and opioid-induced constipation, moderate benefit was found for osmotic or stimulant laxatives; small benefit was found for methylnaltrexone, naldemedine, and electroacupuncture. For patients with cancer and non–opioid-related constipation, moderate benefit was found for naloxegol, prucalopride, lubiprostone, and linaclotide; trivial benefit was found for acupuncture.

Implications for Practice: Effective strategies for managing opioid-induced and non–opioid-related constipation in patients with cancer include lifestyle, pharmacologic, and complementary approaches.

Supplemental material can be found at https://bit.ly/3c4yewT

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or